It is estimated that in 2025 there will be a total of 226,650 new cases of lung and bronchus cancer in the United States. The highest number of these cases are estimated to be in the state of Florida. This statistic presents the estimated number of new lung and bronchus cancer cases in the United States in 2025, by state.

In 2022, 83.2 males and 69.3 females per 100,000 population in England were registered as newly diagnosed with malignant neoplasm of bronchus and lung. Over the analyzed years, the rate of newly diagnosed cases for male individuals has seen a decrease trend. Conversely, the rate of newly diagnosed cases for females has seen a steady increase over the years. This statistic shows the rate of newly diagnosed cases of lung cancer per 100,000 population in England from 1995 to 2022, by gender.

Cancer Rates for Lake County Illinois. Explanation of field attributes: Colorectal Cancer - Cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine). This is a rate per 100,000. Lung Cancer – Cancer that forms in tissues of the lung, usually in the cells lining air passages. This is a rate per 100,000. Breast Cancer – Cancer that forms in tissues of the breast. This is a rate per 100,000. Prostate Cancer – Cancer that forms in tissues of the prostate. This is a rate per 100,000. Urinary System Cancer – Cancer that forms in the organs of the body that produce and discharge urine. These include the kidneys, ureters, bladder, and urethra. This is a rate per 100,000. All Cancer – All cancers including, but not limited to: colorectal cancer, lung cancer, breast cancer, prostate cancer, and cancer of the urinary system. This is a rate per 100,000.

This statistic shows the amount of registrations of newly diagnosed cases of lung cancer in England in 2021, by age group and gender. In this year, almost ************* cases were reported among men aged 70 to 74 years. It should be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to lung cancer.

Objective: While Hungary is often reported to have the highest incidence and mortality rates of lung cancer, until 2018 no nationwide epidemiology study was conducted to confirm these trends. The objective of this study was to estimate the occurrence of lung cancer in Hungary based on a retrospective review of the National Health Insurance Fund (NHIF) database.Methods: Our retrospective, longitudinal study included patients aged ≥20 years who were diagnosed with lung cancer (ICD-10 C34) between 1 Jan 2011 and 31 Dec 2016. Age-standardized incidence and mortality rates were calculated using both the 1976 and 2013 European Standard Populations (ESP).Results: Between 2011 and 2016, 6,996 – 7,158 new lung cancer cases were recorded in the NHIF database annually, and 6,045 – 6,465 all-cause deaths occurred per year. Age-adjusted incidence rates were 115.7–101.6/100,000 person-years among men (ESP 1976: 84.7–72.6), showing a mean annual change of − 2.26% (p = 0.008). Incidence rates among women increased from 48.3 to 50.3/100,000 person-years (ESP 1976: 36.9–38.0), corresponding to a mean annual change of 1.23% (p = 0.028). Age-standardized mortality rates varied between 103.8 and 97.2/100,000 person-years (ESP 1976: 72.8–69.7) in men and between 38.3 and 42.7/100,000 person-years (ESP 1976: 27.8–29.3) in women.Conclusion: Age-standardized incidence and mortality rates of lung cancer in Hungary were found to be high compared to Western-European countries, but lower than those reported by previous publications. The incidence of lung cancer decreased in men, while there was an increase in incidence and mortality among female lung cancer patients.

Mortality from lung cancer (ICD-10 C33-C34 equivalent to ICD-9 162). To reduce deaths from lung cancer. Legacy unique identifier: P00510

Death rate has been age-adjusted by the 2000 U.S. standard population. Single-year data are only available for Los Angeles County overall, Service Planning Areas, Supervisorial Districts, City of Los Angeles overall, and City of Los Angeles Council Districts.Lung cancer is a leading cause of cancer-related death in the US. People who smoke have the greatest risk of lung cancer, though lung cancer can also occur in people who have never smoked. Most cases are due to long-term tobacco smoking or exposure to secondhand tobacco smoke. Cities and communities can take an active role in curbing tobacco use and reducing lung cancer by adopting policies to regulate tobacco retail; reducing exposure to secondhand smoke in outdoor public spaces, such as parks, restaurants, or in multi-unit housing; and improving access to tobacco cessation programs and other preventive services.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

This dataset contains Cancer Incidence data for Lung Cancer (All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are segmented by sex (Both Sexes, Male, and Female) and age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

Legacy unique identifier: P00508

Distributions of 3-year age-adjusted cancer incidence rates, by SES and HSS, in 611 SEERa counties.

Between 2020 and 2024, the relative five-year survival rate for lung cancer was **** percent among women, and **** percent among men. Survival rates for lung cancer have significantly increased in Norway since 1984.

Abstract Objective: To identify the socioepidemiologic and histopathologic patterns of lung cancer patients in the Middle Euphrates region. Patients and Methods: This study analyzed medical information from lung cancer patients at the Middle Euphrates Cancer Center in Iraq from January 2018 to December 2023. Demographic information (age, gender, residency, and education level) as well as clinical details (histopathological categorization) were obtained. The inclusion criteria included all confirmed lung cancer cases, while cases with inadequate data or non-lung cancer diagnosis were omitted. The data were analyzed using IBM SPSS Statistics (version 26). The data summarized using descriptive statistics, and chi-square tests used to identify correlations between categorical variables at a significance level of p < 0.05. Ethical approval was obtained from the relevant institutional review board. Results: A total of 1162 patients were included with mean age at diagnosis(64.47±11.45) years. Majority of patients are over 60 years (64.4%), followed by (40–60 years), 34%, and the least affected group is under 40 years (1.6%). Males account for the majority of cases (68%), while females about 32%, with male:female ratio that fluctuate around 2:1. Illiterate patients and those with low education levels represent the largest proportion accounting for about 87.9% of the study population. Squamous Cell Carcinoma (SCC) is the most frequent subtype (41.7%), followed closely by Adenocarcinoma (AC) at 37%, and Small Cell Lung Cancer (SCLC), 10.5%. Although SCC is the predominant subtype overall, AC incidence is increasing overtime (from 31.7% in 2018 to 41.4% in 2023) with predominance in females, younger and higher educated groups. While the percentage of SCLC and other less common subgroups remained relatively stable over time, there is a significant reduction in NSCLC-NOS diagnoses (from 11.1% in 2018 to 3.2% in 2023). Conclusions: In Iraq, specifically in the Middle Euphrates region, lung cancer is a major public health issue in the elder age groups. The two main subtypes, SCC and AC, are the main contributors, with obvious increment in AC cases in the recent years. The shifting trends indicate the urgent need for improved screening strategies, focused preventative initiatives, and customized treatment plans in view of changing risk profiles.

Legacy unique identifier: P00509

Additional file 1: Table S1.The change of lung cancer prevalence between 1990 and 2019 at 204 countries andterritories. Table S2. The change oflung cancer incidence between 1990 and 2019 at 204 countries and territories. Table S3. The change of lung cancerYLDs between 1990 and 2019 at 204 countries and territories. YLDs, years livedwith disability.

Five- and 10-year survival rates in the patients with lung or bronchial cancer by ethnic group.

Mortality from lung cancer, directly age-standardised rate, persons, under 75 years, 2004-08 (pooled) per 100,000 European Standard population by Local Authority by local deprivation quintile. Local deprivation quintiles are calculated by ranking small areas (Lower Super Output Areas (LSOAs)) within each Local Authority based on their Index of Multiple Deprivation 2007 (IMD 2007) deprivation score, and then grouping the LSOAs in each Local Authority into five groups (quintiles) with approximately equal numbers of LSOAs in each. The upper local deprivation quintile (Quintile 1) corresponds with the 20% most deprived small areas within that Local Authority. The mortality rates have been directly age-standardised using the European Standard Population in order to make allowances for differences in the age structure of populations. There are inequalities in health. For example, people living in more deprived areas tend to have shorter life expectancy, and higher prevalence and mortality rates of most cancers. Lung cancer accounts for 7% of all deaths among men and in England every year and 4% of deaths among women every year. This amounts to 24% of all cancer deaths among men in England and 18% of all cancer deaths among women in England1. Reducing inequalities in premature mortality from all cancers is a national priority, as set out in the Department of Health’s Vital Signs Operating Framework 2008/09-2010/111. This indicator has been produced in order to quantify inequalities in lung cancer mortality by deprivation. This indicator has been discontinued and so there will be no further updates. Legacy unique identifier: P01406

Deaths from lung cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

Relative 1- and 5-year survival for laryngeal cancer in Finland and Sweden.

ObjectiveHungary has repeatedly been shown to have the highest cancer-related mortality and incidence in Europe. Despite lung cancer being the most abundant malignant diagnosis in Hungary, numerous concerns have been raised recently regarding the bias inherent to reported incidence estimates. Re-analysis of reimbursement claims has been suggested previously by our group as an alternative approach, offering revised figures of lung cancer incidence between 2011 and 2016. Leveraging on this methodology, we aimed at updating Hungarian lung cancer incidence estimates with an additional 5 years (2017–2021), including years affected by the COVID-19 pandemic. Additionally, we also attempted to improve the robustness of estimates by taking additional characteristics of the patient pathway into account.MethodsLung cancer patients between 2011 and 2021 were identified based on reimbursement-associated ICD-10 codes, histology codes and time patterns. Multiple query architectures were tested for sensitivity and compared to official estimates of the Hungarian National Cancer Registry (HNCR). Epidemiological trends were estimated by Poisson-regression, corrected for age and sex.ResultsA total of 89,948 lung cancer patients diagnosed in Hungary between 2011 and 2021 have been identified by our study. In 2019 alone, 7,887 patients were diagnosed according to our optimized query. ESP2013 standardized rate was estimated between 92.5/100,000 (2011) and 78.4/100,000 (2019). In 2019, standardized incidence was 106.8/100,000 for men and 59.7/100,000 for women. Up until the COVID-19 pandemic, lung cancer incidence was decreasing by 3.18% (2.1%–4.3%) yearly in men, while there was no significant decrease in women. Young age groups (40–49 and 50–59) featured the largest improvement, but women aged 60–79 are at an increasing risk for developing lung cancer. The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).ConclusionOur results show that using an optimized approach, re-analysis of reimbursement claims yields robust estimates of lung cancer incidence. According to this approach, the incidence rate of male lung cancer is declining in Hungary, in concordance with the trend observed for lung cancer mortality. Among women aged 60–79, the incidence of lung cancer has risen, requiring more attention in the near future.